We have known since the end of May, 8 weeks ago who the new NDTP CEO is, and sure enough it is the founder of CCA, LLC who know from public records, had a drink line with Coke company years ago and who built and sold a drink line later, in just 2 years.
He founded CCA, LLC (who we know from the shareholder letter is R/M with what is now NDTP and brought in the nano tech of Professor Michael W Fountain, brought in three Warren Buffet grade giants in the financial industry as founders and funding sources, Larry Kubin, Mathias and Yarbrough, who all had key positions funding, founding and running 2 Nadsaq firms and 1 Nyse firm.
Nevada SOS was updated late in May with the annual officers and directors list on Milv, which is now NDTP, showing the same thing OTCmarkets shows, and its the same person, James Hovis that started the Private Biotech in 2003 with Professor Michael W. Fountain that has been researching and developing nano delivery technology that can cross the Blood Brain Barrier to deliver nutrients and drugs to the brain so the brain can self repair #TBI-Brain damage and #Dementia caused #Alzheimers (according to CCA, LLC SEC filings in 2016).
FINRA-was updated in July with the ticker change and name change after the R/S was completed in June. They could not finish and file the SEC filing until the stock was trading again, until the shares were back in accounts, and I suspect they want to wait until the stock has a little trading history under the new ticker (?) before they drop the SEC Filing bomb on the markets??? As we have only traded 12 days now under the new NDTP ticker with our shares back in our accounts.
Step, by step all the boxes have been checked off but one. Last box to check off is the Massive SEC filling. It needs to include all the recent changes, and the name changes and the UPennMed Research Hospital contract must be changed from CCA, LLC to NDTP now, as CCA, LLC confirms the R/M with NDTP, and must be including in the SEC filing (S-1/1-A) that is the final public step to re-registering the shares as fully SEC Reporting.
I think they had a time table to have all this done by April/May that was run off the tracks by the #COVID19 quarantine of Auditors. Then the TA goof in June/July and now they may need to do 1-2, 10-Qs to add to the SEC filing in order for the filing to be considered current financials. Like I said I think their original timeline was an April SEC filing, that would have had 1-2 years of audited annual financials, that got de-railed by the Auditors being forced to shelter in place, and they typically do their audits on site. Hard to do with Banks, and Gov offices shut down in March-May. Or they need to redo the Annual audits and change the reporting period from a calendar year to July 1 2019 to June 30 2020 year basis. One or the other IMHO.
CCA, LLC has been a real, Private Biotech since 2003. 2016 SEC fillings revealed that. Until the SEC S-1/1-A filing drops with all the Public details in one filing, it is and must stay a non reporting, non-pumped by management shell, with no PR stuff. That is what an SEC 15-12G filing is all about, that made the shell dark and safe for reorganization.
We know from the OTCmarkets update 8-9 weeks ago that they hired the Attorney that specializes in the SEC S-1 and 1-A filings.
He must work with the new accounting firm the 8-K reported last year, verify and package the history of the old shell, the CCA, LLC Biotech, the people, the Biotech story, the UPennMed and CCA, LLC Joint Venture research history, and add any last minute financials such as 1st and 2nd quarter Financials, and possibly a change in the annual audit calendar.
Until the SEC filing is dropped, we now have all we are going get, unless I turn up something new from other sources, like patents, and research papers.
All of my posts are strictly opinions and should not be considered to be facts, or investment advise. They are for entertainment purposes only.
